Accessibility StatementSkip Navigation PRINCETON, N.J., Nov. 6, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (OTCQB: PTNT) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the pricing of its underwritten public offering. The offering was led by healthcare-focused, high-quality institutional investors and included participation from the Company's Chief Executive O ...